CTLA4 and neoplasm: Another trial of nivolumab with CTLA4 monoclonal antibody ipilimumab showed an overall response rate of 6% (2 of 32 patients), despite substantial responses in tumor reduction on imaging (73.1% and 58.4%) [76].